Roche reported positive Phase II topline data showing that its once-weekly dual glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptor agonist CT-388 achieved substantial, sustained, and dose-dependent weight loss through 48 weeks Roche reported positive topline results from its Phase II clinical trial, CT388-103, evaluating CT-388, Roches investigational dual glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist being developed for the treatment of obesity
Ingredients: Non Medicinal Ingredients: Olive Oil, Beeswax, Calcium carbonate, Gelatin capsule (Gelatin, Glycerin, Water, Titanium dioxide)
How to Inject Retatrutide Safely and Correctly Retatrutide is given as a subcutaneous injection
Theyve watched patients lose significant weight on GLP-1 medications and decide to pursue treatment themselves
Both injectables offer unique benefits to rejuvenate your body from the inside out